Breakthrough Diabetes Research to Be Commercialized by US-Based Nuvilex, Inc.
November 03, 2014 10:49 ET
|
Nuvilex, Inc.
SYDNEY, AUSTRALIA--(Marketwired - November 03, 2014) - Australian research that has produced a line of insulin producing cells that could eliminate the need for injections for Type 1 diabetics will be...
Nuvilex, Inc. Engaged in "Cutting Edge" Cannabis Preclinical Studies Using Model Compounds With Cell-in-a-Box
October 29, 2014 08:45 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 29, 2014) - Nuvilex, Inc. (OTCQB: NVLX) isn't letting the upcoming mid-term elections or the views in Washington, D.C., on medical marijuana slow down its...
Nuvilex, Inc. Moves Closer to "Bio-Artificial Pancreas" Diabetes Treatment With License for Insulin-Producing Cells
October 21, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 21, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has carefully mapped out its plan to develop a diabetes treatment using the Cell-in-a-Box®
platform technology. It started...
Nuvilex's Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive Big Pharma Target
October 14, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 14, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an...
Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market
July 07, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jul 7, 2014) - Nuvilex, Inc. (OTCQB: NVLX) announced last week that its executives recently met with the company's "global development partners" at the 2014 BIO...
Nuvilex Inc., TD2 and the PCRT Should Draw Great Interest to the Company's Pancreatic Cancer Treatment
June 20, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 20, 2014) - Nuvilex, Inc. (OTCQB: NVLX) can accomplish more in its upcoming preclinical trials than many may realize. With the announcement that Translational...
Nuvilex Heads to the Clinic With an Opportunity to Treat a Wider Range of Cancers
June 12, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 12, 2014) - Nuvilex, Inc. (OTCQB: NVLX) and its shareholders should soon experience an event that, to date, has not been enjoyed by the Maryland biotech...
Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan Drug Status, Funding and Much More in Interview
June 04, 2014 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 4, 2014) - Nuvilex, Inc. (OTCQB: NVLX) President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's...
Nuvilex Now Has Access to $50 Million With New Banking Agreement
June 02, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 2, 2014) - Nuvilex (OTCQB: NVLX) has become quite a busy biotechnology firm of late, and with the announcement of what is now a "two-pronged attack" on pancreatic...
Nuvilex CEO and COO to Sit for Recorded Interview at 50th Annual ASCO Conference This Weekend
May 28, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 28, 2014) - After traveling all over the globe for the better part of the last two months putting the pieces in place for its two-pronged attack on pancreatic...